These Are 5 International Cannabis Markets That You Need To Be Following!

During the last year, we have noticed increasing cannabis sales from international markets all over the world.

Going forward, we expect the trend to become more significant and want our readers to be aware of this. Today, we want to highlight 5 international markets that we expect to continue to attract North American cannabis operators and consider these countries to be attractive long-term growth opportunities.

1. Germany – The country is our favorite cannabis market in the European Union (EU) and we believe the industry is barely in the first inning of a major growth cycle. In the near future, we expect recreational cannabis to be legalized in Germany and we expect the development to create a domino type effect in other EU countries. The country has a large population and we will monitor how the industry continues to advance.
2. Australia – Although we are bullish on the cannabis opportunity in Australia, the market has not been the biggest growth driver for companies that are levered to it. We believe Australia will become a more attractive market when other countries in the Southeast Asia region legalize some form of cannabis.
3. Mexico – We consider Mexico to be the jewel of the Latin American cannabis industry and hope to see clarity on the government’s plan to legalize cannabis. So far the legislation has been met with resistance from the Senate and we believe this has put pressure on companies with leverage to the Latin American market. If cannabis is legalized in Mexico, it would be a major catalyst for the cannabis sector and our readers should be aware of this.
4. Israel – We consider Israel to be one of the most attractive international cannabis markets and have noticed rising sales from companies which are levered to it. When compared to Canada or the US, the cost to cultivate a gram of cannabis is much lower in Israel. As a result, the economics that are associated with cultivating cannabis are much more attractive in Israel and our readers should be aware of this. Another pillar of our thesis on the Israeli cannabis industry is related to its location. By having leverage to Israel, cannabis companies can ship products faster and cheaper to the EU.
5. France – Last year, 31 senators in France co-signed a letter that requested authority to launch a consultation process to propose legislation to legalize recreational cannabis. The senators believe that decriminalization is not the right direction for the country and argued that legalization is a social issue that should be adopted by public authorities. Although we expect the process to legalize recreational cannabis in France to be extensive and time consuming, we believe the push by the senators shows how sentiment has changed in an ultra conservative market.

If you are interested in learning about companies which are positioned to capitalize on the global cannabis market, please send an email to support@technical420.com with the subject “Leading International Cannabis Operators” to be added to our distribution list.

Company Relationship Disclosure

T420 is responsible for the T420 opinions provided in this disclosure except all sources or information provided by other parties were not verified or authenticated and T420 does not undertake to confirm or substantiate or be responsible for such information provided by other parties.

Any Content posted regarding a Profiled Issuer is not a solicitation or recommendation to buy, sell or hold securities. We cannot and do not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. All information should be independently verified. We are not responsible for errors or omissions in our publications, and any opinions expressed are subject to change, without notice. We do not, nor are we under any obligation to undertake due diligence or investigation or authenticate and verify whatsoever regarding Profiled Issuers or any Content posted in relation thereto and we do not receive any verification from the Profiled Issuer regarding the Content we disseminate. Similarly, while we endeavor to facilitate the provision of quality information, we are not responsible for any loss or damages caused or alleged to have been caused by its use nor verify or authenticate or update such information.

This article contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, “believes”, “intends”, “anticipates”, “does not anticipate”, “believes” or variations of these words, expressions or statements, that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, state, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company’s facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal, state and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company’s limited operating and profitability track record; dependence on management; the Company’s need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the impact of the Russia-Ukraine conflict on the global economy; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company’s efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws

Share

Tags

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Technical420.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.

Top Stories